MAZE
Maze Therapeutics, Inc. Common Stock
NASDAQ: MAZE · HEALTHCARE · BIOTECHNOLOGY
$26.58
+3.50% today
Updated 2026-04-30
Market cap
$1.42B
P/E ratio
—
P/S ratio
501.65x
EPS (TTM)
$-3.05
Dividend yield
—
52W range
$8 – $54
Volume
0.9M
Maze Therapeutics, Inc. Common Stock (MAZE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $167.50M | $0.00 |
| Revenue growth (YoY) | — | — | — | -100.0% |
| Cost of revenue | $3.82M | $4.09M | $3.30M | $2.40M |
| Gross profit | $-3.82M | $-4.09M | $167.50M | $-2.40M |
| Gross margin | — | — | 100.0% | — |
| R&D | $88.19M | $73.94M | $83.50M | $108.45M |
| SG&A | $22.83M | $24.61M | $26.42M | $34.45M |
| Operating income | $-111.03M | $-98.55M | $57.59M | $-142.90M |
| Operating margin | — | — | 34.4% | — |
| EBITDA | $-107.21M | $-94.46M | $60.88M | $-140.50M |
| EBITDA margin | — | — | 36.3% | — |
| EBIT | $-111.03M | $-98.55M | $57.59M | $-142.90M |
| Interest expense | — | — | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-114.94M | $-100.42M | $52.23M | $-131.12M |
| Net income growth (YoY) | — | +12.6% | +152.0% | -351.0% |
| Profit margin | — | — | 31.2% | — |